USA flag logo/image

An Official Website of the United States Government

PDE4B Inhibitors For Treating Major Depression

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R44MH091791
Solicitation Year:
2013
Solicitation Topic Code:
NIMH
Solicitation Number:
PA12-088
Small Business Information
TETRA DISCOVERY PARTNERS, LLC
910 ROSEWOOD AVE SE GRAND RAPIDS, MI 49506-3362
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2013
Title: PDE4B Inhibitors For Treating Major Depression
Agency: HHS
Contract: 2R44MH091791-03
Award Amount: $3,003,708.00
 

Abstract:

DESCRIPTION (provided by applicant): Tetra Discovery Partners proposes to develop a new treatment for major depressive disorder based on inhibition of phosphodiesterase 4B (PDE4B). Uniquely, the Tetra drug will address inflammation as a contributor to depression. This is a new mechanism of action for an antidepressant drug which should prove complimentary to current therapeutics. Addressing inflammation will target currently untreatable patients, such as those receiving interferon-a (IFNa) for viral illness, depressed patients with co-morbid psoriasis, inflammatory bowel disease, traumatic brain injury, or post-traumatic stress disorder. Given the limitations of current treatments, there is a need for new medications with novel mechanisms of action. The prevalence of major depression is staggering with around 20% of people experiencing depression at some point in their lives. The company estimates that 10-20% of patients with depression have inflammation and will be ideal candidates for the Tetra drug. The market for antidepressant drugs is expected to grow at a CAGR of 3.2% to US 10.9 billion by 2018. The World Health Organization predicts that by 2020, depression will rival heart disease as the health disorder with the highest disease burden in the world. The Phase II SBIR project will complete chemical optimization of a PDE4B inhibitor for use in human and the preclinical safety and toxicity studies needed for filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for human clinical trials in major depression. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The prevalence of major depression is staggering with around 20% of people experiencing depression at some point in their lives. Thus, there is a need for new medications with novel mechanisms of action. The company proposes to develop phosphodiesterase-4B (PDE4B) inhibitors with a unique antidepressant/anti-inflammatory profile for treating depression.

Principal Investigator:

Mark E. Gurney
616-635-0937
mark@tetradiscovery.com

Business Contact:

Mark Gurney
616-635-0937
mark@tetradiscovery.com
Small Business Information at Submission:

TETRA DISCOVERY PARTNERS, LLC
910 ROSEWOOD AVE SE GRAND RAPIDS, MI 49506-3362

EIN/Tax ID: 127399859
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No